Kashiv BioSciences Secures Major Funding to Fuel Global Expansion and Manufacturing Growth

Kashiv BioSciences, a vertically integrated biopharmaceutical company with operations in the United States and India, has recently secured multiple significant financing deals to advance its global growth strategy, boost manufacturing capacity, and support its pipeline of complex biologic and biosimilar medicines. The funding rounds announced over the past year underscore rising investor confidence in the company’s integrated model and ambitious infrastructure plans.

In April 2025, Kashiv BioSciences entered into a $150 million senior secured debt financing agreement with GoldenTree Asset Management. This credit facility is structured to support the company’s development and expansion of manufacturing capabilities in both the U.S. and India. Kashiv plans to use the funds to accelerate its research and development programs for biosimilars and to scale production at facilities including its Piscataway, New Jersey site and newer sites in India dedicated to monoclonal antibody (MAB) drug substance manufacturing. The New Jersey facility holds approximately 8,500 L capacity, while the Indian facility in Pipan was planned at 37,000 L capacity, aimed at serving global markets including the United States, Europe and other regions. The debt financing is also intended to support working capital needs and broader business purposes. J.P. Morgan acted as the structuring agent for the deal, with Milbank LLP and K&L Gates providing legal advisory services.

In addition to the GoldenTree financing, Kashiv BioSciences secured a substantial financing package from the Union Bank of India to expand biologics manufacturing capacity in Gujarat, India. The company announced that it had received approximately INR 648 crore (around $78 million) in funding through this financing arrangement. The proceeds are earmarked for constructing one of India’s largest single‑use commercial manufacturing facilities in Pipan, near Ahmedabad. At full production, the facility is expected to achieve a capacity of up to 50,000 L, significantly enhancing Kashiv’s ability to produce high‑quality biologics and specialty pharmaceuticals for international markets such as the U.S., Canada and Europe.

Kashiv’s expansion in India aligns with government initiatives under the Gujarat State Biotechnology Mission to strengthen biotechnology infrastructure and attract high‑impact investment into the sector. Representatives from the state mission highlighted the project’s potential to elevate India’s scientific capabilities and generate long‑term, high‑value employment in technical and operational disciplines. The Union Bank of India’s participation as a lender supports national goals such as bolstering India’s advanced manufacturing capacity and contributing to aims like “Atmanirbhar Bharat,” a policy emphasis on self‑reliance in key industries.

According to public investment databases, GoldenTree Asset Management and Tarsadia Investments are among the known investors backing Kashiv BioSciences across its financing history. As of the latest filings, Kashiv has undertaken at least two funding rounds, with GoldenTree leading the recent debt financing and Tarsadia Investments participating in earlier seed‑stage backing.

These financing efforts come amid broader operational milestones for Kashiv BioSciences, including regulatory filings and commercial launches of biosimilar products. The company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration and received acceptance of a Marketing Authorization Application from the European Medicines Agency for a proposed biosimilar candidate. Through strategic agreements and product launches, Kashiv continues to expand its footprint in global markets.

Overall, the combination of substantial debt financing from GoldenTree, targeted capital from the Union Bank of India, and ongoing operational developments signals a period of accelerated growth for Kashiv BioSciences. The funding will likely play a crucial role in scaling manufacturing, advancing product pipelines, and strengthening the company’s position as a global player in the biosimilars and biologics sectors.